Investor Update

Basel, 18 May 2017

Invitation: Roche Analyst Event at ISTH 2017

Monday, 10 July 2017, 6:30pm CEST

We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.

During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:

HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors

HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors

Meeting Information


Monday, 10 July 2017


6:00pm Registration desk opens

6:30pm Start of meeting

7:45pm End of meeting followed by a buffet reception


Hotel Berlin, Berlin
Lützowplatz 17
10785 Berlin

To register for the event, please follow the link (Password: Analyst2017).

Dial in to the conference 10-15 minutes prior to the scheduled start, using the following dial-in numbers (listen-only mode, no live-access to speakers):

+41 (0) 58 310 5000 (Europe and ROW) or
+44 (0) 203 059 5862 (UK) or
+1 (1) 631 570 5613 (USA)

Alternatively a live audio webcast can be accessed via The presentation slides will be available from the IR website at following to the closure of the ISTH meeting.

A replay of the webcast will be available on demand on the Roche website.

Best regards,

Karl Mahler
Head of Investor Relations

Sabine Borngräber
Investor Relations Officer